Current and historical daily PE Ratio for EXEL (
Exelixis Inc
) from 2000 to Apr 27 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Exelixis stock (EXEL) PE ratio as of Apr 27 2024 is 36.86.
More Details
Exelixis Inc (EXEL) PE Ratio (TTM) Chart
Exelixis Inc (EXEL) PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Total 1221
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Exelixis PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-27 | 36.9 | 2024-02-26 | 34.1 |
| 2024-04-26 | 36.9 | 2024-02-23 | 33.5 |
| 2024-04-25 | 36.6 | 2024-02-22 | 32.2 |
| 2024-04-24 | 36.9 | 2024-02-21 | 32.2 |
| 2024-04-23 | 36.2 | 2024-02-20 | 32.1 |
| 2024-04-22 | 35.6 | 2024-02-19 | 31.9 |
| 2024-04-19 | 35.0 | 2024-02-16 | 31.9 |
| 2024-04-18 | 35.0 | 2024-02-15 | 32.0 |
| 2024-04-17 | 35.6 | 2024-02-14 | 31.7 |
| 2024-04-16 | 35.5 | 2024-02-13 | 31.5 |
| 2024-04-15 | 35.3 | 2024-02-12 | 31.7 |
| 2024-04-12 | 35.5 | 2024-02-09 | 31.4 |
| 2024-04-11 | 35.2 | 2024-02-08 | 31.4 |
| 2024-04-10 | 36.8 | 2024-02-07 | 31.4 |
| 2024-04-09 | 36.9 | 2024-02-06 | 34.0 |
| 2024-04-08 | 36.3 | 2024-02-05 | 33.3 |
| 2024-04-05 | 36.0 | 2024-02-02 | 33.4 |
| 2024-04-04 | 36.5 | 2024-02-01 | 33.8 |
| 2024-04-03 | 36.8 | 2024-01-31 | 33.8 |
| 2024-04-02 | 36.3 | 2024-01-30 | 34.0 |
| 2024-04-01 | 36.8 | 2024-01-29 | 34.0 |
| 2024-03-29 | 36.9 | 2024-01-26 | 34.4 |
| 2024-03-28 | 36.9 | 2024-01-25 | 34.4 |
| 2024-03-27 | 37.1 | 2024-01-24 | 34.4 |
| 2024-03-26 | 36.7 | 2024-01-23 | 35.2 |
| 2024-03-25 | 36.9 | 2024-01-22 | 35.2 |
| 2024-03-22 | 37.0 | 2024-01-19 | 35.0 |
| 2024-03-21 | 37.2 | 2024-01-18 | 34.6 |
| 2024-03-20 | 36.9 | 2024-01-17 | 35.0 |
| 2024-03-19 | 36.5 | 2024-01-16 | 35.0 |
| 2024-03-18 | 36.0 | 2024-01-15 | 35.3 |
| 2024-03-15 | 35.7 | 2024-01-12 | 35.3 |
| 2024-03-14 | 35.2 | 2024-01-11 | 34.9 |
| 2024-03-13 | 35.9 | 2024-01-10 | 35.5 |
| 2024-03-12 | 35.3 | 2024-01-09 | 36.2 |
| 2024-03-11 | 34.9 | 2024-01-08 | 35.0 |
| 2024-03-08 | 34.5 | 2024-01-05 | 36.1 |
| 2024-03-07 | 34.4 | 2024-01-04 | 36.7 |
| 2024-03-06 | 34.8 | 2024-01-03 | 36.9 |
| 2024-03-05 | 34.6 | 2024-01-02 | 37.2 |
| 2024-03-04 | 35.1 | 2024-01-01 | 37.3 |
| 2024-03-01 | 34.6 | 2023-12-29 | 37.3 |
| 2024-02-29 | 34.1 | 2023-12-28 | 37.5 |
| 2024-02-28 | 34.1 | 2023-12-27 | 85.0 |
| 2024-02-27 | 33.8 | 2023-12-26 | 84.9 |
Exelixis Inc (EXEL) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Exelixis Inc
NAICS : 541714
SIC : 8731
ISIN : US30161Q1040
Share Class Description:
EXEL: Ordinary SharesDescription
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers